Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Emergent BioSolutions acquires Cangene for $216mm in cash

Executive Summary

Vaccines developer Emergent BioSolutions Inc. is paying $3.24 in cash per share (a 22% premium)--a total of $216mm--to acquire all the outstanding common stock in public specialty pharmaco Cangene Corp. (majority owned by Apotex Inc.).
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies